Trial Profile
A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AMP 110 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amplimmune; MedImmune
- 17 Nov 2016 Status changed from recruiting to completed.
- 31 Oct 2014 New trial record